Evolutionary algorithms and decision trees for predicting poor outcome after endovascular treatment for acute ischemic stroke
نویسندگان
چکیده
Despite the large overall beneficial effects of endovascular treatment in patients with acute ischemic stroke, severe disability or death still occurs almost one-third patients. These patients, who might not benefit from treatment, have been previously identified traditional logistic regression models, which may oversimplify relations between characteristics and outcome, machine learning techniques, be difficult to interpret. We developed evaluated a novel evolutionary algorithm for fuzzy decision trees accurately identify poor outcome after was defined as having modified Rankin Scale score (mRS) higher equal 5. The created being comprehensible, easily interpretable making its predictions easy explain practitioners. Insights reason predicted can encourage acceptance adaptation practice help manage expectations treatment. compared our proposed method CART, benchmark tree algorithm, on classification accuracy interpretability. significantly outperformed CART: using 5-fold cross-validation average 1090 training set 273 test set, misclassified 77 (standard deviation 7) 83 (±7) CART. mean number nodes (decision leaf nodes) 11 (±2) 26 (±1) CART trees. With an 72% much fewer than used gain insights into predictive value patient contribute development more accurate medical prediction methods improved clarity practitioners
منابع مشابه
[Endovascular treatment for acute ischemic stroke].
The benefit of endovascular treatment (ET) after acute ischemic stroke has long been debated. Recent studies have demonstrated the clinical benefit of ET up to approximately 8 hours after stroke onset, mainly in association with intranenous thrombolysis. The positive effect is higher if ET is initiated early and performed by an experienced team. Current ET techniques include thrombectomy with c...
متن کاملEndovascular Treatment for Acute Ischemic Stroke
From the Stroke Unit and Department of Neurology (A.C., A.S., R.S.), the Neuro interventional Unit and Department of Neuroradiology (L.V., E.B.), and the Bio statistics Service and Hematology De partment (M.N.), Niguarda Ca’ Granda Hospital, Milan; the Stroke Unit and Department of Neurology, Carlo Poma Hospital, Mantua (A.C.); and the Epide miology and Medical Statistics Section, Departmen...
متن کاملEndovascular Treatment for Acute Ischemic Stroke
To the Editor: In the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) trial, reported by Kidwell et al. (March 7 issue),1 22 participating centers enrolled 118 patients during the period from 2004 through 2011. Thus, on average, each participating center enrolled 1 patient every 16 months. This extremely low rate may suggest that inclusion in the trial was ...
متن کاملHypotension During Endovascular Treatment of Ischemic Stroke Is a Risk Factor for Poor Neurological Outcome.
BACKGROUND AND PURPOSE In retrospective studies, patients receiving general anesthesia for endovascular treatment for acute ischemic stroke have worse neurological outcome compared with patients receiving conscious sedation. It has been suggested that this is caused by general anesthesia-associated hypotension. We investigated the effect of intraprocedural hypotension on neurological outcome. ...
متن کاملNew and future endovascular treatment strategies for acute ischemic stroke.
Cerebral revascularization strategies for acute ischemic stroke have been developed during the past decade. Many of these strategies are currently being evaluated and gaining in popularity, offering hope to those with an otherwise nihilistic disease. Herein, the authors discuss the current progress toward these goals and the efforts being made to develop a safe and efficacious method of clot re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Computers in Biology and Medicine
سال: 2021
ISSN: ['0010-4825', '1879-0534']
DOI: https://doi.org/10.1016/j.compbiomed.2021.104414